RT Journal Article SR Electronic T1 SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation JF bioRxiv FD Cold Spring Harbor Laboratory SP 2020.04.01.021196 DO 10.1101/2020.04.01.021196 A1 Qiang Zhang A1 Huajun Zhang A1 Kun Huang A1 Yong Yang A1 Xianfeng Hui A1 Jindong Gao A1 Xinglin He A1 Chengfei Li A1 Wenxiao Gong A1 Yufei Zhang A1 Cheng Peng A1 Xiaoxiao Gao A1 Huanchun Chen A1 Zhong Zou A1 Zhengli Shi A1 Meilin Jin YR 2020 UL http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, and rapidly spread worldwide. Previous studies suggested cat could be a potential susceptible animal of SARS-CoV-2. Here, we investigated the infection of SARS-CoV-2 in cats by detecting specific serum antibodies. A cohort of serum samples were collected from cats in Wuhan, including 102 sampled after COVID-19 outbreak, and 39 prior to the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for the receptor binding domain (RBD) of SARS-CoV-2 by indirect enzyme linked immunosorbent assay (ELISA). Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies with a titer ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II feline infectious peritonitis virus (FIPV). Our data demonstrates that SARS-CoV-2 has infected cat population in Wuhan during the outbreak.